The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

The present invention discloses an organic compound represented by the following formula (1) and an organic electroluminescence device using the organic compound as the phosphorescent host material, the fluorescent host material, or the fluorescent dopant material. The organic compound may increase a current efficiency or half-life of the organic electroluminescence device.

##STR00001##

The same definition as described in the present invention.

The present invention discloses an organic compound represented by the following formula (1) and an organic electroluminescence device using the organic compound as the phosphorescent host material, the fluorescent host material, or the fluorescent dopant material. The organic compound may increase a current efficiency or half-life of the organic electroluminescence device.

##STR00001##

The same definition as described in the present invention.

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

##STR00001##

The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.

The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.

The present invention discloses a novel polyheteroaromatic compound derived from 7,7-dimethyl-5,7-dihydrospiro[cyclopenta[1,2-b:5,4-b-dithiophene-4,13-indeno[1,2-b]acridine] core structures. The polyheteroaromatic compound can be used as organic electroluminescence materials for use in an organic electroluminescence device and electronic equipment.

The present invention discloses a novel polyheteroaromatic compound derived from 7,7-dimethyl-5,7-dihydrospiro[cyclopenta[1,2-b:5,4-b-dithiophene-4,13-indeno[1,2-b]acridine] core structures. The polyheteroaromatic compound can be used as organic electroluminescence materials for use in an organic electroluminescence device and electronic equipment.